FIGURE 1.

MFSD2A enhances the efficacy of anti‐PD‐1 immunotherapy in GC‐bearing mice. MFSD2A‐overexpressed MFC cells or control cells (5 × 10⁵ cells in 100 μL PBS) were injected subcutaneously into 615 mice. When the tumor grew to 100 mm³, the mice were injected intraperitoneally with PD‐1 antibody or control IgG every 3 days. (A) The expression of MFSD2A in indicated tumor tissues was analyzed by IHC. (B) Growth curves of subcutaneously transplanted tumors in indicated groups of mice. (C) The weight of tumors in indicated groups was calculated and analyzed on the 27th day. (D) The overall survival of tumor‐bearing mice in indicated groups. The mice were considered "dead" when the tumor grew to 2000 mm³ or natural death. All values are presented as the mean ± SEM. * P < 0.05; ** P < 0.01; NS, not significant. Abbreviations: MFSD2A, Major Facilitator Superfamily Domain Containing 2A; PD‐1, programmed cell death protein 1; IHC, immunohistochemistry; GC, gastric cancer; SEM, standard error of the mean.